Stevens Capital Management LP cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.1% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 157,718 shares of the biopharmaceutical company’s stock after selling 1,747 shares during the quarter. Stevens Capital Management LP’s holdings in Gilead Sciences were worth $10,655,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its stake in shares of Gilead Sciences by 1.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 5,129,197 shares of the biopharmaceutical company’s stock worth $320,822,000 after acquiring an additional 51,905 shares during the last quarter. Nordea Investment Management AB lifted its holdings in shares of Gilead Sciences by 14.1% in the fourth quarter. Nordea Investment Management AB now owns 1,026,174 shares of the biopharmaceutical company’s stock valued at $64,186,000 after purchasing an additional 127,140 shares in the last quarter. Gradient Investments LLC lifted its holdings in shares of Gilead Sciences by 260.6% in the first quarter. Gradient Investments LLC now owns 3,880 shares of the biopharmaceutical company’s stock valued at $252,000 after purchasing an additional 2,804 shares in the last quarter. Buckley Wealth Management LLC lifted its holdings in shares of Gilead Sciences by 8.7% in the first quarter. Buckley Wealth Management LLC now owns 32,232 shares of the biopharmaceutical company’s stock valued at $2,095,000 after purchasing an additional 2,574 shares in the last quarter. Finally, Augustine Asset Management Inc. lifted its holdings in shares of Gilead Sciences by 11.4% in the first quarter. Augustine Asset Management Inc. now owns 58,148 shares of the biopharmaceutical company’s stock valued at $3,780,000 after purchasing an additional 5,969 shares in the last quarter. 78.87% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have recently issued reports on the company. Mizuho set a $88.00 target price on Gilead Sciences and gave the company a “buy” rating in a report on Monday, July 15th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Monday, July 15th. Cowen restated a “buy” rating on shares of Gilead Sciences in a report on Friday, May 3rd. JPMorgan Chase & Co. restated a “buy” rating and issued a $85.00 target price on shares of Gilead Sciences in a report on Wednesday, July 31st. Finally, Raymond James increased their target price on Gilead Sciences from $83.00 to $86.00 and gave the company a “strong-buy” rating in a report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $82.29.
NASDAQ GILD traded up $0.59 during trading on Tuesday, hitting $64.57. 247,137 shares of the company traded hands, compared to its average volume of 6,310,354. The company has a market cap of $82.62 billion, a P/E ratio of 10.50, a P/E/G ratio of 3.10 and a beta of 1.16. The business’s fifty day simple moving average is $66.52. Gilead Sciences, Inc. has a 12 month low of $60.32 and a 12 month high of $79.61. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.76 and a quick ratio of 3.67.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.68 by $0.14. The company had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.54 billion. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. The firm’s revenue was down 2.8% compared to the same quarter last year. During the same period last year, the business posted $1.91 earnings per share. On average, equities research analysts predict that Gilead Sciences, Inc. will post 6.65 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.90%. The ex-dividend date of this dividend is Thursday, September 12th. Gilead Sciences’s dividend payout ratio is currently 40.98%.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Further Reading: Why do corrections happen?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.